Revenue: As of FY2026 Q2, the actual value is USD 872.3 M, beating the estimate of USD 839.98 M.

EPS: As of FY2026 Q2, the actual value is USD 2.15, beating the estimate of USD 2.072.

EBIT: As of FY2026 Q2, the actual value is USD 177.9 M.

Net Sales

West Pharmaceutical Services, Inc. reported net sales of $872.3 million for the second quarter of 2026, an increase of 13.8% compared to the prior-year period, with organic growth at 12.7%.

Segment Revenue (Q2 2026)

• Proprietary Products: Net sales increased by 16.6% to $722.6 million, with organic growth of 15.5%.
  • High-Value Product (HVP) Components: Net sales were $424.1 million, up 19.4% (18.4% organic), accounting for 49% of total company net sales.
  • HVP Delivery Devices: Net sales were $131.2 million, up 29.6% (29.2% organic), accounting for 15% of total company net sales.
  • Standard Products: Net sales were $167.3 million, up 2.4% (0.7% organic), accounting for 19% of total company net sales.
• West Vantage: Net sales increased by 2.0% to $149.7 million, with organic growth of 0.8%, accounting for 17% of total company net sales.

Revenue by Market Group (Q2 2026)

• Biologics: Revenue was $374.8 million, with a 30.3% year-over-year (YoY) change and 29.2% organic change.
• Pharma: Revenue was $205.0 million, with a 3.3% YoY change and 1.6% organic change.
• Generics: Revenue was $142.8 million, with a 6.9% YoY change and 6.7% organic change.

Revenue by Geography (Q2 2026)

• Americas: Revenue was $388.7 million, with an 11.2% YoY change and 10.6% organic change.
• Europe, Middle East, Africa: Revenue was $399.8 million, with a 14.3% YoY change and 12.1% organic change.
• Asia Pacific: Revenue was $83.8 million, with a 24.9% YoY change and 27.0% organic change.

Net Income

Net income for the second quarter was $154.0 million. For the six months ended June 30, 2026, net income was $292.8 million.

Gross Profit and Margin

Consolidated gross profit was $329.2 million for the second quarter, representing a gross profit margin of 37.7%, an increase of 200 basis points (bps) year-over-year. Proprietary Products: Gross profit was $308.0 million, with a gross profit margin of 42.6%, up 250 bps YoY. West Vantage: Gross profit was $21.2 million, with a gross profit margin of 14.2%, a decrease of -330 bps YoY.

Operating Profit and Margin

Reported operating profit for the second quarter was $179.1 million, with a reported operating profit margin of 20.5%. Adjusted operating profit was $197.4 million, with an adjusted operating profit margin of 22.6%, up 230 bps compared to Q2 2025. Proprietary Products: Operating profit was $211.9 million, with an operating profit margin of 29.3%, an increase of 320 bps YoY. West Vantage: Operating profit was $12.9 million, with an operating profit margin of 8.6%, down -350 bps YoY.For the six months ended June 30, 2026, reported operating profit was $356.2 million, and adjusted operating profit was $378.4 million.

Operating Costs (Q2 2026)

• Research and development expenses were $19.7 million.
• Selling, general and administrative expenses totaled $117.6 million.
• Other expense (income), net, was $12.8 million.

Cash Flow (Six Months Ended June 30, 2026)

Operating cash flow was $213.9 million. Capital expenditures were $85.9 million. Free cash flow was $128.0 million.

Share Repurchases and Dividends

During the first six months of 2026, West Pharmaceutical Services, Inc. repurchased 1.8 million shares for $454.3 million at an average price of $258.03 per share. A third-quarter 2026 dividend of $0.22 per share was declared on July 21, 2026.

Other Financial Data (As of June 30, 2026)

• Total Assets: $4,076.4 million.
• Total Liabilities: $1,086.2 million.
• Total Equity: $2,990.2 million.
• Cash and cash equivalents: $435.8 million.

Outlook / Guidance

West Pharmaceutical Services, Inc. is raising its full-year 2026 net sales guidance to a range of $3.345 billion to $3.380 billion, representing reported growth of 8.8% to 10.0% and organic growth of 10.0% to 11.0%. Full-year 2026 adjusted-diluted EPS guidance is increased to a range of $8.85 to $9.05, and capital spending guidance remains unchanged at $250 million to $275 million. For the third quarter of 2026, net sales are expected to be between $820 million and $835 million, with adjusted-diluted EPS projected in the range of $2.14 to $2.24, and the estimated tax rate for 2026 is approximately 19%.